GI Lecture 14: Overview of the Liver
HoyaDocs — GI Block | USMLE Step 1 Preparation
GI Lecture 14 — Overview
Overview of the Liver · HoyaDocs GI Block
Page Summaries
Dual blood supply · Hepatic acinus zones · Kupffer cells · Hepatomegaly · Cirrhosis · Ascites vs. edema
Practice Qs: 1–3
Carbohydrate · Lipid · Cholesterol · Protein · Urea cycle · Liver failure signs · HMG-CoA reductase · Statins
Practice Qs: 4–7
Heme → unconjugated → conjugated bilirubin · 4 jaundice types · Lab differentiation · Congenital hyperbilirubinemias
Practice Qs: 8–10
Primary/secondary bile acids · Conjugation · EHC sequence · CCK vs. secretin · Cholecystectomy · Ileal resection
Practice Qs: 11–15
Official Learning Objectives Map
LO 1–2 — Liver Structure & Clinical Conditions
STATE main functions and blood supplies · DEFINE hepatomegaly, jaundice, cirrhosis, ascites · DISTINGUISH ascites from edema
- LO 1: STATE the main functions and blood supplies of the liver — dual blood supply, hepatic architecture, acinus zones, Kupffer cells
- LO 2: DEFINE hepatomegaly, jaundice, cirrhosis, and ascites; DISTINGUISH ascites from peripheral edema
▼ Hepatic Blood Supply & Vascular Architecture
Dual Blood Supply
The liver has a unique dual blood supply, receiving blood from two sources simultaneously:
| Vessel | Flow Rate | O₂ Saturation | Content |
|---|---|---|---|
| Portal Vein | ~1,000 mL/min (70–75%) | Low (venous) | Nutrient-rich blood from GI tract and spleen |
| Hepatic Artery | ~350 mL/min (25–30%) | High (arterial) | Oxygen-rich blood from celiac axis |
Together, these deliver approximately 30% of resting cardiac output to the liver. Despite the portal vein's lower oxygen saturation, each vessel contributes roughly 50% of the liver's total oxygen delivery due to the high portal flow volume.
Hepatic Architecture — Acinus Zones
The hepatic acinus (Rappaport model) is the functional unit organized around a portal triad. Divided into 3 zones based on O₂ and nutrient exposure:
| Zone | Location | O₂/Nutrient Status | Primary Metabolic Roles | Vulnerability |
|---|---|---|---|---|
| Zone 1 (Periportal) | Adjacent to portal triad | High (first to receive) | Gluconeogenesis, β-oxidation, urea synthesis | Viral hepatitis, phosphorus toxicity |
| Zone 2 (Mid-zonal) | Intermediate | Intermediate | Mixed | Yellow fever |
| Zone 3 (Centrilobular) | Adjacent to central vein | Low (last to receive) | Glycolysis, lipogenesis, drug metabolism (CYP450) | Ischemia, acetaminophen, alcohol, halothane |
Hepatic Cell Types
- Hepatocytes (~80%): Parenchymal cells; perform metabolic, secretory, and detoxification functions
- Kupffer Cells: Resident macrophages lining sinusoids; phagocytose bacteria, old RBCs, and portal blood debris; largest population of resident macrophages in the body
- Hepatic Stellate Cells (Ito cells): Store vitamin A in quiescent state; when activated by injury → myofibroblasts → collagen production → fibrosis/cirrhosis
- Sinusoidal Endothelial Cells: Fenestrated; allow free exchange between sinusoidal blood and hepatocytes
- Zone 3 (centrilobular) most susceptible to ischemia and acetaminophen toxicity (highest CYP2E1 concentration)
- Zone 1 (periportal) most susceptible to viral hepatitis injury
- Portal vein = 75% of blood flow, but each vessel contributes ~50% of hepatic O₂
- Kupffer cells = resident macrophages; hepatic stellate cell activation → cirrhosis mechanism
- Liver receives 30% of cardiac output — second highest perfusion after the kidneys (per gram)
▼ Main Functions of the Liver
The liver performs three major categories of function:
| Category | Key Functions | Failure Consequences |
|---|---|---|
| Metabolic | Carbohydrate homeostasis; lipid synthesis/oxidation; protein synthesis; amino acid metabolism | Hypoglycemia, hypoalbuminemia, coagulopathy, hyperammonemia |
| Secretory | Bile production (600–1000 mL/day); cholesterol excretion; bilirubin conjugation and excretion | Jaundice, steatorrhea, fat-soluble vitamin deficiency (A, D, E, K) |
| Detoxification | CYP450 drug metabolism; first-pass effect; ammonia → urea; hormone inactivation (estrogen, aldosterone) | Drug toxicity, hepatic encephalopathy, spider angiomata (↑estrogen) |
Additional functions: lymph production (~50% of total body lymph), immune surveillance (Kupffer cells), iron storage (ferritin), and fat-soluble vitamin storage (A, D, K, B₁₂).
▼ Clinical Definitions: Hepatomegaly, Jaundice, Cirrhosis & Ascites
Hepatomegaly
Definition: Liver enlargement exceeding ~12–15 cm by percussion in the mid-clavicular line. Causes: infection (hepatitis, EBV, CMV), fatty liver disease (NAFLD/NASH), congestive heart failure ("nutmeg liver"), malignancy (HCC, metastasis), infiltrative disease (sarcoidosis, amyloid).
Jaundice (Icterus)
Definition: Yellow discoloration of skin, sclerae, and mucous membranes due to elevated serum bilirubin (>2–3 mg/dL). First visible in the sclerae due to high elastin content (elastin binds bilirubin). Full classification covered in LO 5 tab.
Cirrhosis
Definition: Irreversible replacement of normal hepatic parenchyma with fibrous scar tissue and regenerative nodules, distorting hepatic architecture. Common causes:
- Chronic alcohol use (most common in the US)
- Chronic viral hepatitis (B and C)
- Non-alcoholic steatohepatitis (NASH)
- Metabolic: Wilson's disease (↑copper), hemochromatosis (↑iron), α-1 antitrypsin deficiency
- Autoimmune hepatitis; primary biliary cholangitis (PBC); primary sclerosing cholangitis (PSC)
Consequences: Portal hypertension → varices, ascites, splenomegaly; hepatic synthetic dysfunction → ↓albumin, ↓clotting factors; encephalopathy (↑ammonia); HCC risk.
Ascites
Definition: Accumulation of excess fluid in the peritoneal cavity (>25 mL abnormal; clinically detectable at ~500–1000 mL). Pathophysiology in cirrhosis involves three converging mechanisms:
- Portal hypertension → ↑hydrostatic pressure in portal capillaries → fluid transudation into peritoneum
- Hypoalbuminemia (↓hepatic synthesis) → ↓plasma oncotic pressure → fluid leaves vasculature
- Splanchnic vasodilation (NO-mediated) → effective arterial underfilling → RAAS activation → Na⁺/H₂O retention → worsens accumulation
| Feature | Ascites | Peripheral Edema |
|---|---|---|
| Location | Peritoneal cavity | Subcutaneous tissue (ankles, legs) |
| Required component | Portal hypertension (in addition to possible ↓oncotic pressure) | ↑Capillary hydrostatic pressure OR ↓oncotic pressure (no portal HTN required) |
| Causes | Cirrhosis, right heart failure, malignancy, TB | Right heart failure, nephrotic syndrome, venous insufficiency, hypoalbuminemia alone |
| Diagnosis | Shifting dullness, fluid wave; confirmed by ultrasound; SAAG distinguishes etiology | Pitting on pressure in dependent areas |
| SAAG | ≥1.1 g/dL → portal HTN etiology; <1.1 → malignancy, TB, nephrotic | Not applicable |
Key point: Hypoalbuminemia alone (e.g., nephrotic syndrome) causes bilateral leg edema and possibly periorbital edema — but NOT ascites unless portal hypertension coexists. Ascites = portal HTN is the key distinguishing driver.
- Pre-hepatic: Portal vein thrombosis → ↑portal pressure, normal liver function, normal LFTs
- Intra-hepatic (sinusoidal): Cirrhosis (most common); hepatic venous outflow obstruction (Budd-Chiari)
- Post-hepatic: Budd-Chiari syndrome (hepatic vein thrombosis); constrictive pericarditis; right heart failure
- Sequelae: esophageal varices, hemorrhoids, caput medusae, splenomegaly, ascites
- SAAG ≥1.1 g/dL = portal HTN. SAAG <1.1 = exudative etiology (malignancy, TB peritonitis)
LO 3–4 — Metabolic Functions of the Liver
DESCRIBE metabolic functions and associated pathology · IDENTIFY cholesterol uses and dietary effects on synthesis
- LO 3: DESCRIBE the metabolic functions of the liver and associated pathology — carbohydrate, lipid, protein metabolism, and detoxification
- LO 4: IDENTIFY the main uses of cholesterol and how dietary cholesterol affects endogenous synthesis via HMG-CoA reductase
▼ Carbohydrate Metabolism
The liver is central to glucose homeostasis, acting as both a glucose buffer (fed state) and glucose producer (fasting state):
| Process | State | Hormonal Control | Outcome |
|---|---|---|---|
| Glycogenesis | Fed (postprandial) | Insulin ↑ | Glucose → glycogen stored in liver (up to ~100 g) |
| Glycogenolysis | Short-term fasting | Glucagon ↑, Epinephrine ↑ | Glycogen → glucose released into blood |
| Gluconeogenesis | Prolonged fasting/stress | Glucagon ↑, Cortisol ↑ | Amino acids, lactate, glycerol → glucose |
| Glycolysis | Fed (high glucose) | Insulin ↑ | Glucose → pyruvate → acetyl-CoA (energy/lipid synthesis) |
Clinical Correlation: Liver Failure & Glucose
- Acute liver failure: Loss of glycogen stores + impaired gluconeogenesis → profound hypoglycemia — a hallmark of acute (not chronic) liver failure and a poor prognostic sign
- The liver uses GLUT2 (constitutive, insulin-independent) for glucose uptake — not GLUT4
- Chronic liver disease: insulin resistance common; impaired glycogen storage
▼ Lipid Metabolism & Lipoproteins
- Fatty acid β-oxidation: Occurs in mitochondria (Zone 1 predominant); generates acetyl-CoA → TCA cycle. Excess → ketone bodies (acetoacetate, β-hydroxybutyrate) — fuel for brain/heart during starvation
- De novo lipogenesis: Excess glucose → fatty acids via acetyl-CoA + malonyl-CoA. Occurs when glycogen stores are saturated (fed state, excess carbohydrate)
- VLDL synthesis: Liver packages triglycerides + cholesterol + apoB100 → VLDL → secreted → peripheral TG extraction → IDL → LDL
- HDL: Liver produces nascent HDL (apoAI); performs reverse cholesterol transport from periphery back to liver
Lipoprotein Summary
| Lipoprotein | Origin | Primary Cargo | Clinical Significance |
|---|---|---|---|
| Chylomicrons | Intestinal epithelium | Dietary TG (exogenous pathway) | Degraded by lipoprotein lipase (LPL) in capillaries; remnants taken up by liver |
| VLDL | Liver | Endogenous TG | ↑ in hypertriglyceridemia, metabolic syndrome, alcohol use |
| LDL | Derived from VLDL | Cholesterol (to periphery) | "Bad cholesterol"; atherogenic; lowered by statins (↑LDLR expression) |
| HDL | Liver & intestine | Cholesterol (from periphery) | "Good cholesterol"; reverse cholesterol transport; ↑ with exercise |
- Insulin resistance → ↑lipolysis in adipose → ↑FFA delivery to liver + impaired β-oxidation + ↓VLDL export → triglyceride accumulation in hepatocytes
- Spectrum: steatosis → NASH (+ inflammation/ballooning) → fibrosis → cirrhosis → HCC
- Most common cause of chronic liver disease in the US
▼ Cholesterol Metabolism & Statins (LO 4)
Uses of Cholesterol
- Cell membranes: Structural component; modulates membrane fluidity
- Bile acids: Primary bile acids synthesized from cholesterol (rate-limiting enzyme: cholesterol 7α-hydroxylase / CYP7A1)
- Steroid hormones: Glucocorticoids, mineralocorticoids, sex hormones (estrogen, testosterone, progesterone, aldosterone)
- Vitamin D: 7-dehydrocholesterol in skin → vitamin D₃ on UV exposure
- Myelin sheath: Critical for neural myelination
HMG-CoA Reductase — Rate-Limiting Step
The rate-limiting step in cholesterol synthesis: HMG-CoA → mevalonate, catalyzed by HMG-CoA reductase.
Feedback regulation:
- High dietary/intracellular cholesterol → SREBP-2 cleavage inhibited → ↓HMG-CoA reductase transcription → ↓endogenous synthesis
- Low intracellular cholesterol → ↑LDLR expression → more LDL uptake from blood
Statins (atorvastatin, simvastatin, rosuvastatin): Competitive inhibitors of HMG-CoA reductase → ↓hepatic cholesterol → upregulate LDL receptors → ↑LDL clearance from plasma → ↓serum LDL by 30–50%. Side effects: myopathy (↑CK), rhabdomyolysis (rare), transaminase elevation.
High dietary cholesterol → suppresses (not stimulates) HMG-CoA reductase via feedback inhibition. Endogenous hepatic synthesis decreases as a compensatory response.
However, dietary cholesterol also downregulates LDL receptors in the liver, reducing LDL clearance. The net effect is a modest ↑serum LDL with high dietary cholesterol.
Saturated fat has a stronger effect on serum LDL than dietary cholesterol (by downregulating LDLR more potently) — this is why dietary guidelines focus on limiting saturated fat, not just cholesterol intake.
Bile acid sequestrants (cholestyramine) bind bile acids in the gut → disrupt EHC → liver converts more cholesterol to bile acids (↑CYP7A1) → ↓intrahepatic cholesterol → ↑LDLR expression → ↓serum LDL. This is the indirect path to cholesterol lowering.
- HMG-CoA reductase = rate-limiting step of cholesterol synthesis; target of statins
- Statins → ↓intrahepatic cholesterol → ↑LDLR upregulation → ↑LDL clearance from plasma → ↓serum LDL
- Familial hypercholesterolemia = LDLR mutation → markedly ↑LDL despite normal HMG-CoA reductase
- Abetalipoproteinemia = apoB deficiency → cannot form chylomicrons or VLDL → fat-soluble vitamin deficiency, acanthocytosis, ataxia
- Ezetimibe: blocks NPC1L1 in intestinal brush border → ↓dietary cholesterol absorption → complementary to statins
▼ Protein Metabolism & Detoxification
Hepatic Protein Synthesis
The liver synthesizes virtually all major plasma proteins except immunoglobulins (produced by plasma cells):
- Albumin: Most abundant plasma protein; maintains oncotic pressure; carrier for drugs, hormones, fatty acids, bilirubin. Half-life ~20 days → ↓albumin is a chronic marker of liver synthetic dysfunction
- Clotting factors: All factors except factor VIII (made by endothelium/megakaryocytes). Vitamin K–dependent: II, VII, IX, X, protein C, protein S. Factor VII has the shortest half-life (~4–6 hrs) → PT/INR rises earliest in liver failure
- Carrier proteins: Transferrin, ceruloplasmin, haptoglobin, α-1 antitrypsin, sex hormone–binding globulin (SHBG)
- Acute phase reactants (↑): CRP, fibrinogen, haptoglobin, α-1 antitrypsin, ferritin (↑ with inflammation)
- Negative acute phase reactants (↓): Albumin, transferrin, prealbumin (transthyretin) — decrease with inflammation
Amino Acid Metabolism & Urea Cycle
- Transamination: ALT (alanine aminotransferase) and AST (aspartate aminotransferase) — ALT more liver-specific; AST also in muscle, heart
- Deamination: Removes amino group → NH₃ (ammonia)
- Urea cycle (hepatocytes only): NH₃ → citrulline → argininosuccinate → arginine → urea + ornithine → urea excreted by kidneys. In liver failure: hyperammonemia → hepatic encephalopathy
- Treatment: lactulose (traps NH₄⁺ in gut, promotes excretion) + rifaximin (↓ammonia-producing bacteria)
Detoxification & First-Pass Metabolism
- Phase I (CYP450): Oxidation, reduction, hydrolysis — converts lipophilic compounds to slightly more polar metabolites. Site: Zone 3 hepatocytes (↑CYP2E1 for acetaminophen/APAP)
- Phase II: Conjugation (glucuronidation, sulfation, acetylation, glutathione) → highly water-soluble metabolites → excreted in bile or urine
- First-pass effect: Orally ingested drugs absorbed from gut → portal vein → liver → substantial metabolism before reaching systemic circulation. Explains why oral bioavailability is lower than IV (e.g., oral morphine dose >> IV dose)
- ↓Albumin → ↓oncotic pressure → ascites, edema, ↑free drug levels (altered pharmacokinetics)
- ↓Clotting factors (II, VII, IX, X) → ↑PT/INR; factor VII (shortest t½) rises first
- ↓Urea cycle → hyperammonemia → hepatic encephalopathy (asterixis, confusion, coma)
- ↓Gluconeogenesis/glycogenolysis → hypoglycemia (especially in acute liver failure)
- ↓Estrogen metabolism → ↑estrogen → spider angiomata, palmar erythema, gynecomastia, testicular atrophy
- ↓Bile production → steatorrhea, fat-soluble vitamin deficiency (A, D, E, K)
LO 5 — Bilirubin Metabolism & Jaundice
DESCRIBE bilirubin metabolism · DISTINGUISH the 4 types of jaundice and their lab profiles
- LO 5: DESCRIBE bilirubin metabolism and distinguish the 4 types of jaundice — hemolytic, hepatocellular, obstructive, and neonatal — including lab differentiation
▼ Bilirubin Metabolism: Step-by-Step Pathway
Bilirubin is the end product of heme catabolism. The pathway spans from the spleen through the liver to the intestines:
| Step | Location | Process | Product |
|---|---|---|---|
| 1 | Spleen / RES macrophages | Aged RBCs phagocytosed → hemoglobin → heme + globin | Heme |
| 2 | Spleen / macrophages | Heme oxygenase: heme → biliverdin + CO + Fe²⁺ | Biliverdin (green) |
| 3 | Spleen / macrophages | Biliverdin reductase: biliverdin → bilirubin | Unconjugated bilirubin (indirect; fat-soluble, albumin-bound, toxic) |
| 4 | Bloodstream | Unconjugated bilirubin bound to albumin; transported to liver | Albumin–bilirubin complex |
| 5 | Hepatocyte | Uptake via OATP transporters; conjugation with glucuronic acid by UGT1A1 | Conjugated bilirubin (direct; water-soluble, non-toxic) |
| 6 | Bile canaliculi | Secreted via MRP2 transporter → bile duct → duodenum | Bile (yellow-green color) |
| 7 | Large intestine | Gut bacteria deconjugate bilirubin → urobilinogen (colorless) | Urobilinogen |
| 8a | Colon → stool | Urobilinogen oxidized → stercobilin | Stercobilin — brown stool color |
| 8b | Colon → portal vein → kidney | ~20% urobilinogen reabsorbed → liver re-excretes or kidney excretes | Urobilin — yellow urine color |
- Unconjugated (indirect) bilirubin: Fat-soluble; bound to albumin; cannot be filtered by kidneys → not in urine; can cross blood-brain barrier → kernicterus in neonates
- Conjugated (direct) bilirubin: Water-soluble; can be filtered by kidneys → bilirubinuria (dark urine) when elevated in blood; cannot cross BBB
▼ 4 Types of Jaundice & Lab Differentiation
| Type | Mechanism | Direct Bili | Indirect Bili | Urine Bili | Urobilinogen | Stool |
|---|---|---|---|---|---|---|
| Hemolytic (Pre-hepatic) | ↑RBC destruction → overwhelms conjugation capacity | Normal | ↑↑ | Negative | ↑↑ | Dark (↑stercobilin) |
| Hepatocellular (Intrahepatic) | Damaged hepatocytes: ↓conjugation + regurgitation of conjugated bili into blood | ↑ | ↑ | Positive | Variable (↓ or normal) | Normal to pale |
| Obstructive (Post-hepatic) | Bile duct obstruction → conjugated bili cannot drain → backs up into blood | ↑↑ | Normal/mild ↑ | Positive (dark urine) | ↓ or absent | Pale/clay-colored |
| Neonatal (Physiologic) | Immature UGT1A1 + high fetal Hgb turnover | Normal | ↑↑ | Negative | Variable | Normal |
Congenital Hyperbilirubinemias (Step 1 Favorites)
| Condition | Defect | Bili Type | Key Clinical Feature |
|---|---|---|---|
| Gilbert Syndrome | ↓UGT1A1 promoter (mild, 30–50% reduction) | ↑Indirect | Benign; jaundice triggered by fasting, illness, exercise; very common (5–10% of population) |
| Crigler-Najjar Type I | Complete absence of UGT1A1 | ↑↑Indirect | Severe; kernicterus in infancy; requires liver transplant |
| Crigler-Najjar Type II | Reduced UGT1A1 activity (<10% normal) | ↑Indirect | Responds to phenobarbital (induces CYP/UGT expression) |
| Dubin-Johnson | Defective MRP2 (↓conjugated secretion) | ↑Direct | Black liver on autopsy (melanin-like pigment); benign prognosis |
| Rotor Syndrome | Defective OATP1B1/1B3 (↓hepatocyte uptake) | ↑Direct | Similar to Dubin-Johnson; normal liver color on biopsy |
Obstructive jaundice presents with a classic triad:
- Dark urine (bilirubinuria) — conjugated bilirubin enters bloodstream → filtered by kidneys
- Pale/clay-colored stools — bilirubin never reaches gut → no stercobilin → acholic stools
- Pruritus — bile salts depositing in skin (intense itching, often worse at night)
Contrast with hemolytic jaundice: dark stools (↑stercobilin from excess bilirubin reaching gut), no bilirubinuria (unconjugated cannot pass into urine), ↑↑urobilinogen in urine.
Courvoisier sign (painless jaundice + palpable non-tender gallbladder) = pancreatic head malignancy until proven otherwise. The gallbladder is distended because it has been gradually obstructed — in gallstone disease, chronic inflammation usually fibroses the gallbladder wall (Courvoisier's law).
- Unconjugated = indirect = fat-soluble = albumin-bound = NOT in urine = neurotoxic (kernicterus)
- Conjugated = direct = water-soluble = CAN appear in urine = dark urine in obstructive/hepatic jaundice
- Obstructive jaundice: ↑direct bili, dark urine, clay stools, ↓urobilinogen, pruritus; ↑ALP (cholestasis marker)
- Hemolytic jaundice: ↑indirect bili, no bilirubinuria, ↑urobilinogen, dark stools
- Neonatal jaundice: phototherapy converts unconjugated bilirubin to lumirubin (water-soluble) → excreted without conjugation
- Gilbert syndrome = most common cause of unconjugated hyperbilirubinemia; benign; fasting precipitant
LO 6–10 — Bile, Enterohepatic Circulation & Clinical Predictions
IDENTIFY bile constituents · STATE conjugation significance & EHC sequence · DESCRIBE secretion/storage · LIST regulation · PREDICT clinical effects
- LO 6: IDENTIFY bile acid constituents, production site, and factors affecting composition
- LO 7: STATE the significance of conjugation and the full sequence of enterohepatic circulation
- LO 8: STATE mechanisms of bile secretion and gallbladder storage/concentration
- LO 9: LIST the factors that regulate bile secretion (CCK, secretin, bile salts, vagus, somatostatin)
- LO 10: PREDICT the effects of cholecystectomy and ileal resection on fat digestion and absorption
▼ Bile Constituents & Production (LO 6)
Bile is an aqueous secretion produced by hepatocytes (~600–1,000 mL/day), modified by cholangiocytes (ductal bicarbonate secretion). Serves two primary roles: fat emulsification and excretion of cholesterol, bilirubin, and toxins.
Bile Composition
| Component | % Solutes | Function / Note |
|---|---|---|
| Bile salts | ~67% | Emulsify fats; form micelles; derived from primary bile acids conjugated with taurine/glycine |
| Phospholipids (lecithin) | ~22% | Solubilize cholesterol in mixed micelles; protect bile duct epithelium from bile acid toxicity |
| Cholesterol | ~4% | Primary route of cholesterol excretion from the body |
| Conjugated bilirubin | ~0.3% | Responsible for bile color; excreted → urobilinogen → stercobilin |
| Water, ions (Na⁺, HCO₃⁻) | Remainder | Secretin stimulates ductal HCO₃⁻ secretion; alkalinizes duodenum |
Primary Bile Acids
Synthesized de novo in hepatocytes from cholesterol. Rate-limiting enzyme: cholesterol 7α-hydroxylase (CYP7A1).
- Cholic acid (trihydroxy)
- Chenodeoxycholic acid (dihydroxy)
▼ Bile Acid Conjugation & Enterohepatic Circulation (LO 7)
Conjugation of Bile Acids
Before secretion, bile acids are conjugated in hepatocytes with taurine or glycine → bile salts:
- Cholic acid + glycine/taurine → glycocholic acid / taurocholic acid
- Chenodeoxycholic acid → similarly conjugated
Significance of conjugation:
- ↓pKa → ionized at intestinal pH → cannot be passively reabsorbed in small intestine → stays in lumen for emulsification
- More effective at micelle formation; less toxic to gut epithelium
- Increases water solubility for biliary secretion
Secondary Bile Acids (Formed by Gut Bacteria)
In the distal ileum and colon, bacteria deconjugate and 7α-dehydroxylate primary bile acids:
- Cholic acid → Deoxycholic acid
- Chenodeoxycholic acid → Lithocholic acid (poorly absorbed; mostly excreted; hepatotoxic in excess)
Enterohepatic Circulation (EHC) — Full Sequence
- Hepatocytes synthesize primary bile acids → conjugate with taurine/glycine → bile salts
- Bile salts secreted into canaliculi → common bile duct → duodenum (via sphincter of Oddi)
- Bile salts emulsify dietary fats throughout the small intestine; form mixed micelles for fat absorption
- Terminal ileum: ~95% of bile salts actively reabsorbed via ASBT (apical sodium-dependent bile acid transporter)
- Absorbed bile salts enter portal vein → return to liver (hepatic extraction ~90–95%)
- Liver reconjugates and re-secretes → cycle repeats 6–10× per day
- ~5% escapes into colon → converted to secondary bile acids → excreted in feces (= small daily loss replaced by new synthesis)
- Primary bile acids: cholic acid + chenodeoxycholic acid (made in liver from cholesterol)
- Secondary bile acids: deoxycholic acid + lithocholic acid (formed by gut bacteria)
- Conjugation with taurine/glycine → bile salts — more soluble, ionized at intestinal pH, better emulsification
- Terminal ileum absorbs 95% via ASBT — loss here cannot be compensated by increased hepatic synthesis alone
- Bile acid sequestrants (cholestyramine): bind bile acids in gut → ↑CYP7A1 → ↑cholesterol → bile acid synthesis → ↓serum LDL
▼ Bile Secretion & Gallbladder Storage (LO 8)
Two-Stage Hepatic Bile Secretion
- Stage 1 — Hepatocytes: Bile salts actively secreted via BSEP (bile salt export pump); organic anions (conjugated bilirubin) via MRP2 → osmotic water flow → canalicular bile forms
- Stage 2 — Cholangiocytes (bile duct epithelium): Modify canalicular bile → absorb bile acids; secrete HCO₃⁻ and water (stimulated by secretin via cAMP/CFTR) → alkaline modification neutralizes duodenal acid
Gallbladder: Storage & Concentration
- Between meals: sphincter of Oddi contracts → bile diverted to gallbladder (capacity ~40–70 mL)
- Gallbladder mucosa actively absorbs Na⁺, Cl⁻, HCO₃⁻, and water → bile concentrated 5–20× (average ~10×)
- Result: highly concentrated bile (↑bile salts, ↑cholesterol, ↑bilirubin) → ↑gallstone risk especially with bile stasis (fasting, pregnancy, TPN)
▼ Regulation of Bile Secretion (LO 9)
| Regulator | Stimulus | Effect on Bile | Mechanism |
|---|---|---|---|
| CCK | Fat + protein entering duodenum (I cells) | ↑Gallbladder contraction + sphincter of Oddi relaxation → bile delivery to duodenum; also stimulates pancreatic enzyme secretion | CCK1 receptors on gallbladder smooth muscle; also via vagus |
| Secretin | Acid (H⁺) in duodenum (S cells) | ↑Ductal HCO₃⁻ secretion → alkaline bile; does NOT contract gallbladder | Secretin receptors on cholangiocytes → cAMP → CFTR → Cl⁻/HCO₃⁻ exchange |
| Bile salts (choleresis) | Bile salts returning in portal blood | ↑Hepatic bile secretion (bile salt-dependent fraction) | Direct osmotic effect + FXR-mediated transcription |
| Vagal stimulation | Cephalic phase (sight/smell of food) | ↑Bile secretion; mild gallbladder contraction | ACh on gallbladder and cholangiocytes |
| Somatostatin | D cells (stomach/intestine) | ↓Gallbladder contraction; ↓bile secretion | Inhibits CCK release; direct gallbladder inhibition |
- CCK (fat/protein → I cells): Contracts gallbladder + relaxes sphincter of Oddi → bile flows out. Also stimulates pancreatic enzyme secretion. "Fat calls for CCK."
- Secretin (acid → S cells): Stimulates ductal and pancreatic bicarbonate secretion. Neutralizes acid in duodenum. Does NOT contract the gallbladder.
- Both are released postprandially and act synergistically for fat digestion.
- Sphincter of Oddi normally stays contracted (tone); CCK relaxes it to allow bile flow.
▼ Clinical Predictions: Cholecystectomy & Ileal Resection (LO 10)
Cholecystectomy (Gallbladder Removal)
What changes: Loss of reservoir → bile drips continuously from the liver into the duodenum (no concentrated bolus with meals).
Clinical consequences:
- Total daily bile acid production unchanged; only the delivery pattern changes
- Most patients tolerate cholecystectomy well with small, low-fat meals
- Large fatty meals → inadequate bile bolus → bloating, loose stools, fatty food intolerance
- Post-cholecystectomy syndrome: Persistent pain/dyspepsia (sphincter of Oddi dysfunction, bile reflux, retained CBD stone)
Ileal Resection or Disease (Crohn's Disease of Terminal Ileum)
Terminal ileum = site of ASBT (active bile salt reabsorption). Resection or disease destroys this critical reabsorption site:
- Bile salts not reabsorbed → lost in feces
- Bile acid pool depletes (liver cannot synthesize enough to compensate)
- Insufficient bile salt concentration in small intestine → impaired fat emulsification → steatorrhea
- Fat-soluble vitamin malabsorption: A, D, E, K → vitamin K deficiency → coagulopathy
- Excess bile salts reaching colon → stimulate colonic Cl⁻/water secretion → bile acid diarrhea (cholerheic diarrhea)
- Also: vitamin B₁₂ malabsorption (also absorbed in terminal ileum → intrinsic factor–B₁₂ complex) → megaloblastic anemia
- Small resection (<100 cm): Liver compensates with ↑synthesis; bile acid diarrhea predominates → treat with cholestyramine
- Large resection (>100 cm): Pool depleted → steatorrhea + fat-soluble vitamin deficiency predominate → treat with low-fat diet + fat-soluble vitamin supplementation
- Cholecystectomy: Continuous bile drip → impaired large fatty meal digestion; no baseline malabsorption; generally well-tolerated
- Small ileal resection: ↑Bile acids in colon → secretory diarrhea; treat with cholestyramine
- Large ileal resection: Depleted bile acid pool → steatorrhea + fat-soluble vitamin deficiency (A, D, E, K); treat with low-fat diet + supplements
- Cholestyramine paradox: treats both high LDL (binds bile acids → ↑hepatic synthesis → ↓serum cholesterol) AND bile acid diarrhea (binds bile acids in colon)
- Terminal ileum also absorbs vitamin B₁₂ → ileal resection → B₁₂ deficiency → megaloblastic anemia (treat with IM B₁₂)
Practice Questions
15 USMLE Step 1–style questions covering LOs 1–10
Question 1 — LO 1 (Hepatic Blood Supply)
A 45-year-old man undergoes right hepatic lobectomy. The surgeons note two vessels entering the liver hilum. Which of the following best describes the relative contributions of these vessels to hepatic oxygen delivery?
A) Portal vein provides 75% of blood flow and 75% of oxygen
B) Portal vein provides 75% of blood flow but only ~50% of oxygen
C) Hepatic artery provides 25% of blood flow but ~75% of oxygen
D) Both vessels contribute equally to blood flow and oxygen delivery
E) Hepatic artery provides 50% of blood flow and 75% of oxygen
The portal vein delivers ~70–75% of total hepatic blood flow (~1,000 mL/min) but carries venous (deoxygenated) blood. The hepatic artery provides ~25–30% of flow (~350 mL/min) but is fully oxygenated arterial blood. Despite the flow disparity, each vessel contributes approximately 50% of the liver's total oxygen delivery. This dual supply protects against ischemia — ligation of either vessel alone is usually survivable.
Question 2 — LO 1 (Hepatic Acinus Zones)
A patient presents with acute liver failure following acetaminophen overdose. Liver biopsy shows centrilobular (zone 3) necrosis. Which of the following best explains why zone 3 is most vulnerable to acetaminophen toxicity?
A) Zone 3 receives blood first from portal triads, maximizing drug exposure
B) Zone 3 has the highest concentration of CYP2E1 and receives the least oxygen
C) Zone 1 hepatocytes are protected by proximity to the central vein
D) Zone 3 expresses the highest glucokinase, making it susceptible to oxidative stress
E) Kupffer cells concentrated in zone 3 cause immune-mediated destruction
Zone 3 (centrilobular) is farthest from portal triads → least oxygen and nutrients. It also has the highest concentration of CYP2E1, the enzyme that converts acetaminophen to the toxic metabolite NAPQI (N-acetyl-p-benzoquinoneimine). When glutathione is depleted, NAPQI causes covalent protein binding and hepatocyte necrosis. Zone 1 (periportal) is most vulnerable to viral hepatitis. Zone 3 is most susceptible to ischemia and drug/alcohol toxicity.
Question 3 — LO 2 (Ascites Pathophysiology)
A 54-year-old man with alcoholic cirrhosis has progressive abdominal distention. Paracentesis reveals SAAG of 1.4 g/dL. Serum albumin is 2.1 g/dL. Which of the following best describes the primary mechanism driving ascites in this patient?
A) Hypoalbuminemia alone shifts fluid into the peritoneal cavity
B) Portal hypertension combined with hypoalbuminemia increases net filtration into the peritoneal space
C) Right heart failure elevates central venous pressure, causing hepatic sinusoidal congestion
D) Lymphatic obstruction prevents reabsorption of peritoneal fluid
E) Aldosterone excess causes direct peritoneal fluid accumulation
Cirrhotic ascites requires portal hypertension as the key driver: ↑hydrostatic pressure in portal capillaries → fluid transudation. Hypoalbuminemia (↓hepatic synthesis) lowers oncotic pressure, worsening fluid shifts. SAAG ≥1.1 g/dL confirms portal HTN as the etiology. Hypoalbuminemia alone (e.g., nephrotic syndrome) causes peripheral edema, not ascites, because there is no portal hypertension component. Aldosterone contributes to total Na⁺/H₂O retention but does not directly cause peritoneal accumulation.
Question 4 — LO 3 (Hypoglycemia in Liver Failure)
A 26-year-old woman presents with acute liver failure after ingesting Amanita phalloides mushrooms. Her blood glucose is 35 mg/dL. Which two hepatic processes, when lost, best explain this severe hypoglycemia?
A) Glycolysis and de novo lipogenesis
B) Glycogenolysis and gluconeogenesis
C) Ketogenesis and β-oxidation
D) Glycogenesis and glycolysis
E) Protein synthesis and urea cycle
The liver maintains blood glucose during fasting via two mechanisms: (1) Glycogenolysis — mobilizing hepatic glycogen stores (up to ~100 g) and (2) Gluconeogenesis — synthesizing glucose from amino acids (alanine, glutamine), lactate (Cori cycle), and glycerol. Acute liver failure eliminates both → profound hypoglycemia. This is a hallmark of acute (not chronic) liver failure and requires IV dextrose supplementation. Note: GLUT2 (not GLUT4) is the constitutive hepatic glucose transporter — insulin-independent uptake.
Question 5 — LO 3 (Hepatic Encephalopathy)
A 62-year-old man with cirrhosis develops confusion, asterixis, and ammonia level of 120 µmol/L. His PT is 22 seconds and albumin is 2.0 g/dL. Which hepatic metabolic failure best explains his neurological symptoms?
A) Hypoalbuminemia reduces blood-brain barrier oncotic pressure
B) Prolonged PT causes microhemorrhages throughout the CNS
C) Failure of the urea cycle leads to hyperammonemia and CNS dysfunction
D) Hypoglycemia from impaired gluconeogenesis is the primary cause
E) Elevated unconjugated bilirubin crosses the blood-brain barrier
The liver is the sole site of the urea cycle, converting toxic ammonia (NH₃) to non-toxic urea. In cirrhosis, hepatocyte loss impairs this conversion → hyperammonemia. Ammonia crosses the blood-brain barrier → astrocyte swelling, neurotransmitter imbalance (↑GABA inhibitory tone, glutamate depletion), and cerebral edema → encephalopathy. Precipitants: GI bleeding (protein load), infections, dehydration, constipation, benzodiazepines. Treatment: lactulose (acidifies gut → NH₄⁺ trapping + catharsis) + rifaximin (↓ammonia-producing bacteria).
Question 6 — LO 3 (Lipid Metabolism — NAFLD)
A 52-year-old obese man with type 2 diabetes has liver biopsy showing macrovesicular steatosis with lobular inflammation. Which of the following best explains the mechanism of hepatic lipid accumulation?
A) Decreased dietary fat reduces β-oxidation, causing hepatic lipid storage
B) Insulin resistance increases free fatty acid delivery to the liver, impairs β-oxidation, and reduces VLDL export
C) Decreased HMG-CoA reductase activity leads to cholesterol esterification in hepatocytes
D) Kupffer cell activation directly increases hepatocyte triglyceride synthesis
E) Excess bile acid production deposits lipids in hepatocytes
NASH develops via insulin resistance: (1) Adipose lipolysis is uninhibited → excess free fatty acids (FFAs) flood the liver; (2) Mitochondrial β-oxidation is impaired, so FFAs accumulate; (3) VLDL export of packaged triglycerides is insufficient. Net result: macrovesicular steatosis. A second hit (oxidative stress, inflammatory cytokines) drives progression to NASH → fibrosis → cirrhosis → HCC. NAFLD is now the most common cause of chronic liver disease in the Western world.
Question 7 — LO 4 (Statins — Mechanism)
A 58-year-old woman starts atorvastatin for elevated LDL cholesterol. Six weeks later, her LDL has decreased by 42%. Which of the following best describes the mechanism by which statins lower serum LDL?
A) Statins inhibit intestinal NPC1L1, blocking dietary cholesterol absorption
B) Statins block HMG-CoA reductase → ↓hepatic cholesterol → upregulation of LDL receptors → ↑LDL clearance from blood
C) Statins activate lipoprotein lipase in peripheral capillaries → increased LDL catabolism
D) Statins bind bile acids in the intestinal lumen → increased fecal cholesterol excretion
E) Statins stimulate VLDL secretion by the liver, shifting cholesterol away from LDL
Statins competitively inhibit HMG-CoA reductase (rate-limiting step of cholesterol synthesis) → ↓intracellular hepatic cholesterol → SREBP-2 activation → ↑LDL receptor (LDLR) transcription → more LDL captured from plasma → ↓serum LDL. (A) = ezetimibe mechanism; (C) = fibrates mechanism (for hypertriglyceridemia); (D) = bile acid sequestrants (cholestyramine/colesevelam). Side effects of statins: myopathy (↑CK), rhabdomyolysis (rare), ↑LFTs.
Question 8 — LO 5 (Bilirubin Conjugation)
A medical student is reviewing bilirubin metabolism. She notes that unconjugated bilirubin is transported to the liver bound to albumin, where it undergoes conjugation. What is the primary purpose of this conjugation reaction?
A) To make bilirubin fat-soluble for incorporation into bile micelles
B) To reduce bilirubin's toxicity to erythrocytes in hepatic sinusoids
C) To convert bilirubin to a water-soluble form for biliary and urinary excretion
D) To allow bilirubin to cross the blood-brain barrier for neurological processing
E) To facilitate binding of bilirubin to Kupffer cell receptors for phagocytosis
Hepatocytes conjugate bilirubin with glucuronic acid via UGT1A1 → bilirubin diglucuronide (conjugated/direct bilirubin). Water-solubility allows: (1) secretion into bile canaliculi via MRP2 and (2) urinary excretion if it accumulates in blood (bilirubinuria). (A) is incorrect — unconjugated bilirubin is fat-soluble; conjugation makes it less lipophilic. (D) is the opposite — unconjugated bilirubin crosses the BBB (dangerous!), while conjugated cannot, explaining why neonatal kernicterus involves unconjugated hyperbilirubinemia.
Question 9 — LO 5 (Neonatal Jaundice)
A 3-day-old neonate is jaundiced. Total bilirubin is 14 mg/dL; indirect bilirubin 13.5 mg/dL, direct 0.5 mg/dL. Which of the following best explains why conjugated bilirubin is low in physiologic neonatal jaundice?
A) Immature OATP transporters prevent hepatocyte bilirubin uptake
B) Immature UGT1A1 (UDP-glucuronosyltransferase) activity impairs conjugation
C) MRP2 secretory pumps are absent in neonatal hepatocytes
D) Excess bilirubin production from fetal hemoglobin overwhelms all hepatic processing
E) Neonates lack the gut bacteria needed to convert bilirubin to urobilinogen
Physiologic neonatal jaundice is primarily due to immature UGT1A1 activity in the first days of life. Contributing factors: high fetal hemoglobin (HbF) turnover (shorter neonatal RBC lifespan ~70–90 days vs. 120 days in adults) and breast milk inhibitory factors. Treatment: phototherapy converts unconjugated bilirubin to water-soluble lumirubin photoisomers that can be excreted without conjugation. Risk: if unconjugated bilirubin >~20 mg/dL → kernicterus (bilirubin deposition in basal ganglia) → permanent neurologic damage. If jaundice appears <24 hours → suspect hemolytic disease of newborn (Rh/ABO incompatibility).
Question 10 — LO 5 (Obstructive Jaundice)
A 68-year-old man presents with painless jaundice and 15-lb weight loss over 2 months. Exam reveals a palpable, non-tender gallbladder (Courvoisier sign). Labs: total bilirubin 11 mg/dL, direct bilirubin 9.5 mg/dL, ALP markedly elevated, urine dipstick positive for bilirubin. Which additional finding would be expected?
A) Increased urinary urobilinogen
B) Dark (tarry) stools from excess stercobilin
C) Pale/clay-colored stools and pruritus
D) Elevated reticulocyte count indicating active hemolysis
E) Decreased serum alkaline phosphatase
This is obstructive jaundice from pancreatic head cancer (Courvoisier sign + painless jaundice + weight loss = cancer until proven otherwise). In obstruction: bilirubin cannot reach gut → no stercobilin → pale/clay-colored stools. Conjugated bilirubin backs up into blood → filtered by kidneys → dark urine (bilirubinuria). Bile salts deposit in skin → pruritus. Urobilinogen is absent/decreased (not increased — A is wrong), because no bilirubin reaches the gut to be converted. ↑ALP is the hallmark of cholestasis.
Question 11 — LO 6 (Bile Composition & Gallstones)
A researcher notes that bile normally solubilizes cholesterol despite its low water solubility. Which components of bile keep cholesterol in solution?
A) Conjugated bilirubin and water form a solubilizing complex
B) Bile salts and phospholipids form mixed micelles that incorporate cholesterol
C) Bicarbonate and sodium ions maintain cholesterol in the aqueous phase
D) Mucin glycoproteins secreted by gallbladder epithelium bind cholesterol
E) Secondary bile acids produced by colonic bacteria increase cholesterol solubility
Cholesterol is kept in solution within mixed micelles formed by bile salts and phospholipids (lecithin/phosphatidylcholine). Their amphipathic nature creates hydrophobic cores that sequester cholesterol. When cholesterol exceeds the solubilizing capacity (bile becomes supersaturated → cholesterol saturation index >1), cholesterol crystallizes → cholesterol gallstones (80% of gallstones in the West). Ursodeoxycholic acid (UDCA) treatment dissolves small stones by increasing bile acid pool and reducing cholesterol saturation.
Question 12 — LO 7 (Bile Acid Conjugation)
A patient is treated with broad-spectrum antibiotics for 3 weeks, substantially altering gut microbiome. Which effect on bile acid metabolism would be expected?
A) Increased secondary bile acid production (deoxycholic acid, lithocholic acid)
B) Impaired conjugation of primary bile acids in the liver
C) Decreased conversion of primary to secondary bile acids in the colon
D) Increased enterohepatic circulation efficiency due to reduced bacterial bile acid losses
E) Elevated serum bilirubin due to impaired bilirubin deconjugation
Secondary bile acids (deoxycholic, lithocholic) are formed when gut bacteria deconjugate and 7α-dehydroxylate primary bile acids in the colon. Antibiotics deplete gut microbiome → ↓bacterial enzymatic activity → ↓secondary bile acid formation. The bile acid pool shifts toward primary bile acids. Conjugation happens in the liver (not by bacteria), so option B is incorrect. This is clinically relevant: disrupted microbiome alters bile acid composition and can contribute to metabolic and GI symptoms (relevant to C. difficile colitis pathophysiology as well).
Question 13 — LO 7 (Enterohepatic Circulation — ASBT Inhibitor)
A pharmaceutical company develops a drug that blocks the ASBT (apical sodium-dependent bile acid transporter) in the terminal ileum. Which metabolic effect would be expected?
A) Increased bile acid pool due to reduced biliary secretion
B) Increased hepatic LDL receptor expression and decreased serum LDL cholesterol
C) Decreased hepatic bile acid synthesis due to excess bile acids accumulating in the liver
D) Increased fat-soluble vitamin absorption due to enhanced micelle formation
E) Elevated serum bilirubin due to impaired bilirubin reabsorption
Blocking ASBT → bile salts not reabsorbed → lost in feces → depleted bile acid pool → liver senses low bile acid levels → ↑CYP7A1 (cholesterol 7α-hydroxylase) → more cholesterol converted to bile acids → intracellular hepatic cholesterol ↓ → ↑LDL receptor upregulation → more LDL cleared from plasma → ↓serum LDL. This is the same principle behind bile acid sequestrants (cholestyramine, colesevelam). ASBT inhibitors are being developed as cholesterol-lowering and bile acid diarrhea agents. Side effect: fat-soluble vitamin malabsorption if bile acid pool depleted enough.
Question 14 — LO 8–9 (Bile Regulation)
A 28-year-old woman eats a high-fat meal. Over the next 20 minutes, which sequence of events most accurately describes the biliary response?
A) Secretin release → gallbladder contraction → bile delivery → then HCO₃⁻ secretion
B) CCK release from I cells → gallbladder contraction + sphincter of Oddi relaxation; secretin from S cells → ductal HCO₃⁻ secretion
C) Somatostatin from D cells → gallbladder contraction → bile delivery → CCK inhibition
D) CCK release → sphincter of Oddi contraction → bile retained in gallbladder → stored for next meal
E) Vagal stimulation alone mediates all postprandial bile delivery; no hormonal involvement
Fat/protein entering duodenum → CCK released from I cells → gallbladder smooth muscle contraction + sphincter of Oddi relaxation → bile flows into duodenum. Simultaneously, gastric acid → secretin from S cells → cholangiocytes secrete HCO₃⁻-rich fluid (via cAMP/CFTR) → neutralizes duodenal acid. Key traps: CCK contracts gallbladder (not secretin); sphincter of Oddi is normally contracted and CCK relaxes it (D is backwards); somatostatin inhibits gallbladder contraction (C is wrong).
Question 15 — LO 10 (Ileal Resection)
A 34-year-old woman with Crohn's disease undergoes resection of 130 cm of terminal ileum. Postoperatively she develops voluminous watery diarrhea and oily stools (steatorrhea). Which of the following best explains her symptoms?
A) Loss of ileocecal valve causes rapid intestinal transit, preventing fat digestion
B) Disruption of enterohepatic circulation depletes the bile acid pool (→ steatorrhea) and excess bile acids reaching the colon cause secretory diarrhea
C) Resection removes the site of CCK production, impairing gallbladder contraction and bile delivery
D) Terminal ileum resection impairs vitamin B₁₂ absorption causing anemia and secondary steatorrhea
E) Surgical trauma to mesenteric lymphatics impairs chylomicron transport
Terminal ileum contains ASBT transporters that reabsorb 95% of bile salts. Large resection (130 cm): (1) Depleted bile acid pool → insufficient fat emulsification → steatorrhea + fat-soluble vitamin deficiency; (2) Excess bile acids reaching colon → stimulate Cl⁻/water secretion → secretory (cholerheic) diarrhea. Also: vitamin B₁₂ malabsorption (terminal ileum = absorption site for IF–B₁₂ complex) → megaloblastic anemia over time. CCK is produced in the duodenum/jejunum (C is wrong). Treatment: cholestyramine (for diarrhea in small resections); low-fat diet + fat-soluble vitamin supplements (for large resections).